Headlands Technologies LLC Has $934,000 Stake in United Therapeutics Co. (NASDAQ:UTHR)

Headlands Technologies LLC decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 35.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,647 shares of the biotechnology company's stock after selling 1,464 shares during the quarter. Headlands Technologies LLC's holdings in United Therapeutics were worth $934,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Wealthfront Advisers LLC increased its holdings in shares of United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after purchasing an additional 18,313,424 shares in the last quarter. Norges Bank acquired a new position in United Therapeutics during the fourth quarter worth about $151,764,000. World Investment Advisors LLC purchased a new position in United Therapeutics in the third quarter valued at about $139,206,000. Thrivent Financial for Lutherans lifted its position in shares of United Therapeutics by 1,325.5% during the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company's stock valued at $72,085,000 after acquiring an additional 189,967 shares during the period. Finally, AustralianSuper Pty Ltd boosted its stake in shares of United Therapeutics by 577.1% during the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company's stock worth $66,962,000 after acquiring an additional 161,751 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Finally, StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $388.25.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the transaction, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. This represents a 22.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $940,373.07. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 83,500 shares of company stock worth $29,502,480. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $4.50 on Monday, reaching $287.96. 181,496 shares of the company traded hands, compared to its average volume of 449,565. The stock has a market capitalization of $12.93 billion, a PE ratio of 12.62, a P/E/G ratio of 0.97 and a beta of 0.63. The company's 50 day moving average is $333.78 and its 200-day moving average is $354.54. United Therapeutics Co. has a fifty-two week low of $230.39 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the business posted $4.36 earnings per share. As a group, analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.